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Abstract
Introduction: Zika virus (ZIKV) has caused one of the most challenging global infectious epidemics in recent years because of its
causal association with severe microcephaly and other congenital malformations. The diagnosis of viral infections usually relies on the
detection of virus proteins or genetic material in clinical samples as well as on the infected host immune responses. Serial serologic
testing is required for the diagnosis of congenital infection when diagnostic molecular biology is not possible.
Patient concerns: A 2-year-old girl, born to a mother with conﬁrmed ZIKV infection during pregnancy, with a conﬁrmed ZIKV
infection in utero, showed at birth a severe microcephaly and clinical characteristics of fetal brain disruption sequence compatible
with a congenital ZIKV syndrome (CZS).
Diagnosis: ZIKV-RNA and ZIKV-IgM serological response performed at birth and during the follow-up time tested always negative.
Serial serologic ZIKV-IgG tests were performed to assess the laboratory ZIKV diagnosis, ZIKV-IgG seroreversion was observed at 21
monthsof age.ZIKVdiagnosisof thisbabyhad tobe reliedonher clinical and radiological characteristics thatwerecompatiblewith aCZS.
Interventions: The patient was followed-up as per protocol at approximately 1, 4, 9, 12, 18–21, and 24 months of age.
Neurological, radiological, audiological, and ophthalmological assessment were performed during this period of time. Prompt
rehabilitation was initiated to prevent potential adverse long-term neurological outcomes.
Outcomes: The growth of this girl showed a great restriction at 24 months of age with a weight of 8.5kg (2.5 z-score) and a head
circumference of 40.5cm (4.8 z-score). She also had a great neurodevelopmental delay at the time of this report.
Conclusion:We presume that as a consequence of prenatal ZIKV infection, the fetal brain and other organs are damaged before
birth through direct injury. Following this, active infection ends during intrauterine life, and as a consequence the immune system of
the infant is unable to build up a consistent immune response thereafter. Further understanding of the mechanisms taking part in the
pathogenesis of ZIKV congenital infection is needed. This ﬁnding might change our paradigm regarding serological response in the
ZIKV congenital infection.
Abbreviations: AF = amniotic ﬂuid, CSF = cerebrospinal ﬂuid, CZS = Congenital ZIKV syndrome, DENV = dengue virus, HIV =
Human immunodeﬁciency virus, IgG= immunoglobulin G antibodies, IgM= immunoglobulinM antibodies, MRI=magnetic resonance
imaging, PRNT = plaque reduction neutralization test, RNA = ribonucleic acid, RT-PCR = reverse-transcriptase-polymerase-chain-
reaction, TORCH = Toxoplasma gondii, rubella virus, cytomegalovirus, herpes virus I and II, and HIV, ZIKV = Zika virus.
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 Mother medical history 
Living in Barcelona (Spain) since 2008 
Travel to Colombia (Cartagena and Cordoba) for VFR between 7/12/2015 to 09/01/2016 
Onset of a micropapular exanthema on the 9th January 2016 (3 days of evoluon) 
Consultaon for health assessment on the 27th January 2016 (11 weeks of gestaon) 
12w of gestaon  
Posive IgG and RT-PCR for ZIKV in serum 
Negave IgM for ZIKV in serum 
Normal prenatal US 
04/02/2016 
15w of gestaon  
Posive IgG/IgM and RT-PCR for ZIKV in 
serum 
Normal prenatal US 
26/02/2016 
17w of gestaon  
Posive IgG/IgM and negave RT-PCR for 
ZIKV in serum 
08/03/2016 
21/03/2016 19w of gestaon  
Abnormal prenatal US showing bilateral 
ventriculomegaly 
Amniocentesis: posive RT-PCR for ZIKV  
24/03/2016 19w of gestaon  
Prenatal MRI abnormal showing bilateral 
mild ventriculomegaly, a shortened corpus 
callosum, brain parenchyma calciﬁcaons, 
and severe atrophy (ﬁgure 2) 
25/07/2016 
Birthdate 
Mother Newborn 
At birth  
Clinical characteriscs of CZS 
Posive IgG and negave IgM/RT-PCR for ZIKV in 
serum 
Abnormal cerebral US, CT, and MRI (ﬁgure 3) 
Follow-up at 6, 9, and 12motnhs of age 
Clinical characteriscs of CZS 
Posive IgG and negave IgM/RT-PCR for ZIKV in 
serum 
Follow-up at 21 and 24 motnhs of age 
Clinical characteriscs of CZS 
Negave IgG, IgM, and RT-PCR for ZIKV in serum 
29/11/2017 Abnormal cerebral US, CT, and MRI (ﬁgure 3) 
Figure 1. Case report timeline.
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Zika virus (ZIKV) has caused one of the most challenging global
infectious epidemics in recent years, mainly because of its causal2association with severe microcephaly and other congenital
malformations.[1–4]
The diagnosis of viral infections usually relies on the detection
of virus proteins or genetic material in clinical samples as well as
Figure 2. Fetal MRI showing bilateral mild ventriculomegaly, partial collapsed
skull, and severe atrophy in the fetal brain.
Sulleiro et al. Medicine (2019) 98:20 www.md-journal.comthe infected host’s immune responses. Immunoglobulin G (IgG)
antibodies cross the placenta, and serial serologic testing is
required for the diagnosis of congenital infection when speciﬁc
IgG is detected in the newborn. Transplacentally acquired
maternal IgG usually becomes undetectable by 6 to 12 months of
age, whereas infants with congenital infection show persistence of
IgG antibodies. Before availability of molecular diagnosis,
mother-to-child Human Immunodeﬁciency Virus (HIV) infection3was diagnosed based on persistence of the serological response
beyond the age of 18 months.[5] Likewise, serial serologic testing
is used for the diagnosis of congenital toxoplasmosis.[6]
Seroreversion can be achieved following prompt and adequate
treatment of some congenital infections (e.g., syphilis).[7]2. Case report
We here describe a congenital Zika syndrome (CZS) case of a 2-
year-old girl born in Barcelona to a mother infected with ZIKV
during pregnancy, who presented a complete seroreversion of
ZIKV-IgG serological response (Fig. 1). Her mother was infected
during pregnancy while on a 1-month duration visit from Spain
to Colombia (her country of origin) in December 2015; she was
symptomatic with fever andmicro-papular exanthema at 9weeks
of gestation within 2 weeks after returning to Spain. Following
the US Centers for Disease Control and Prevention (CDC)
protocol,[8] the mother was tested for ZIKV and other ﬂaviviruses
to assess the risk of fetal involvement. ZIKV infection was
conﬁrmed at 11 weeks of gestation, when she tested positive for
ZIKV RNA by reverse-transcriptase–polymerase-chain-reaction
(RT-PCR) assay (RealStar Zika Virus RT-PCR Kit 1.0, Altona
Diagnostics) in serum, and later at 19 weeks in amniotic ﬂuid
(AF). The mother also tested positive for ZIKV-IgG (IIFT,
Arboviral fever Mosaic, Euroimmun, Germany), and for ZIKV
plaque reduction neutralization test (PRNT) achieving a
maximum titer of 1/1024. Serological IgG response to dengue
virus (DENV) tested positive, but was negative for chikungunya
virus. Fetal neurosonography and magnetic resonance imaging
(MRI) revealed bilateral mild ventriculomegaly, a shortened
corpus callosum, brain parenchyma calciﬁcations, and severe
atrophy (Fig. 2). Genetic, Toxoplasma gondii, rubella virus,
cytomegalovirus, herpes virus I and II, andHIV (TORCH) testing
in AF with microarray-based comparative genomic hybridization
(SurePrint G3 Unrestricted CGH ISCA v2 Microarray Kit,
8x60K, Agilent Technologies) and PCRwere respectively normal
and negative.
The infant was delivered by caesarean section at 37 weeks and
one-day gestation because of suspected intrauterine growth
restriction. At birth, all the RT-PCR assays of the maternal
(serum, urine, AF, placenta, membranes, and umbilical cord) and
neonatal samples (serum, urine, cerebrospinal ﬂuid [CSF], and
saliva) were negative for ZIKV (Table 1). In the ﬁrst 24h of life
ZIKV immunoglobulin M (ZIKV-IgM) (IIFT, Arboviral fever
Mosaic, Euroimmun, Germany) was negative in neonatal serum
and CSF, while ZIKV-IgG was positive in both samples. At the
same time, we also tested ZIKV-PRNT with a positive result
(Table 1). Congenital cytomegalovirus infection was ruled out by
PCR in urine.
Microcephaly (Table 1), and features of fetal brain
disruption sequence[1,2] were present at birth, including severe
microcephaly, craniofacial disproportion, partially collapsed
skull, prominent occiput, and excess nuchal skin. Neurological
exam showed irritability, hyperexcitability, exacerbation of the
primitive reﬂexes, inconsolable crying, and joint contractures.
Postnatal ultrasonography, computed tomography and MRI
studies conﬁrmed the microcephaly with a thinned corpus
callosum and brain atrophy with parenchymal calciﬁcations
(Fig. 3). Ophthalmological examination was normal. Hearing
test by brainstem auditory evoked potentials was normal.
Clinical and radiological features were considered compatible
with CZS.[1–3]
Table 1
Clinical and laboratory results of the Congenital Zika Syndrome case.
Age
Data
Birth 6 months 9 months 12 months 21 months 24 months
Anthropometrics
Weight (z-score)
∗
2,540g (0.8) 6390g (1.1) 7050g (1.2) 7,300g (1.6) 8,470g (1.8) 8550g (2.5)
Length (z-score)
∗
48cm (0.4) 64cm (0.7) 70cm (0.06) 73cm (0.2) 79cm (0.9) 83cm (0.8)
Head circumference (z-score)
∗
30cm (2.24) 35.5cm (5.1) 37cm (5.0) 38cm (5.0) 39.5cm (5.0) 40.5 cm (4.8)
Samples
Blood
Hb (gr/dL) 15.9 12.5 13.6
Hct. (%) 46 35.9 38.7
Leukocytes (per mm3) 15,690 9,930 7,010
Neutrophils (per mm3) 11,200 1,800 1,800
Lymphocytes (per mm3) 2,600 7,000 4,300
Platelets (per mm3) 252,000 411,000 419,000
AST (UI/L) 22 21
ALT (UI/L) 5 15
Serum
RT-PCR ZIKV Negative Negative Negative Negative Negative
IgM-ZIKV† Negative Negative Negative Negativex Negative
IgG-ZIKV† Positive Positive Positive Negativex Negative
PRNT ZIKV‡ Positive†
IgM-DENV Negative Negative Negative
IgG-DENV Positive (2.34) Negative Negative
IgM-CMV Negative
IgG-CMV Negative
IgM-CHKV Negative
IgG-CHKV Negative
Urine
RT-PCR ZIKV Negative
RT-PCR CMV Negative
Saliva
RT-PCR ZIKV Negative Negative
CSF
Leukocytes (per mm3) 3
Erithrocytes (per mm3) 40
Glucose (mg/dL) 43
Proteins (mg/dL) 214
RT-PCR ZIKV Negative
IgG ZIKV (IIFT) Positive
IgM ZIKV (IIFT) Negative
∗
For z-scores, intergrowth-21st standards were used in the neonatal period and WHO Child Growth Standards were used thereafter.
† Tested by IIFT (Arboviral fever Mosaic, Euroimmun, Germany) from birth to 18 months and ELISA (ELISA Zika virus IgM and ELISA Zika virus IgG, Euroimmun, Germany) from 21 to 24 months of age.
‡ Performed in the Spanish National Reference Center for Arboviruses (ISCIII-Madrid).
x Studied in our center and conﬁrmed by the Spanish National Reference Center for Arboviruses (ISCIII-Madrid).
Sulleiro et al. Medicine (2019) 98:20 MedicineThe patient was followed-up as per protocol at approximately
1, 4, 9, 12, 18–21, and 24 months of age, by a multidisciplinary
team. During the follow-up period she stayed in Barcelona, with
no travel to arboviral-endemic areas. Her growth showed
major restriction and at 24 months her weight was 8.5kg
(2.5 z-score) and head circumference was 40.5cm (4.8 z-
score) (Table 1). The patient never tested positive for any of the
molecular biological tests or speciﬁc ZIKV-IgM. Her ZIKV-IgG
response was monitored throughout follow-up, and serorever-
sion was ﬁrst observed in May 2018 (at 21 months of age) being
conﬁrmed at 24 months of age (Table 1). However, we could not
perform a new lumbar puncture after seroreversion to check the
ZIKV-IgG response in CSF because the mother declined this
additional investigation. The mother remained positive for
ZIKV-IgG and DENV-IgG in July 2018, when her daughter
was 2 years old.4Ethics committee of the Hospital Universitari Vall d’Hebron
approved the data collection registry for this case and also
for all the children born to ZIKV-infected mothers
(PR(AMI)103/2016).3. Discussion
CZS due to mother-to-child transmitted ZIKV infection has been
documented extensively in the recent epidemic.[1,2] The case we
describe here has the distinctive clinical and radiological features
of CZS (Table 1). Moreover, we have evidence that the mother
was infected, at least once, in early pregnancy as ZIKV was
detected in serum in association with clinical symptoms. Indeed,
the detection of ZIKV RNA in the AF conﬁrmed the involvement
of the fetus and constitutes the only laboratory evidence of
prenatal infection in this child.
Figure 3. Axial CT (A), axial (B), and sagittal (C) T2-weighted MR images showing microcephaly and skull collapse. There is moderate ventricular dilatation,
enlargement of extra-axial cerebrospinal ﬂuid spaces and thinning of brain parenchyma. The gyral pattern is abnormally smooth for gestational age. Subcortical
calciﬁcations are predominantly located in the frontal lobes. Axial (D) and (E) T2-weighted, and coronal (F) T1-weighted follow-up MR images registered at 16-
month-old showing the same pattern observed at birth.
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partly due to the narrow time-frame for the detection of the ZIKV
RNA. Additionally, the considerable antigenic homology
between ZIKV and DENV can cause cross-reactivity in
serological assays. In our case, we were unable to demonstrate
ZIKV congenital infection by RT-PCR or ZIKV-IgM in postnatal
samples. As inferred from other well-known congenital infections
such as HIV and Toxoplasma, we initially interpreted the
persistence of ZIKV-IgG in serum as the best serological marker
to conﬁrm congenital ZIKV infection due to the lack of evidence
from other laboratory tests. However, seroreversion of ZIKV-
IgGwas ﬁrst observed at 21months of age, and then conﬁrmed at
24 months (Table 1).
To our knowledge, this is the ﬁrst description of a case of ZIKV
congenital infection showing a non-permanent serological
IgG response alongside the characteristic clinical phenotype.
Furthermore, the location of this case in Europe and the absence
of travel to endemic areas (thus no vectorial transmission risk)
means that we have described the true serological response to
prenatal ZIKV infection in early fetal life. We hypothesize that
the following mechanisms could explain our ﬁndings. First, the
low and transient ZIKV viremia, compared to reported DENV
infections,[9] could lead to a lack of ZIKV levels of antigen
detection, and additionally to the absence of a strong immune
response. Second, the speciﬁc and direct tropism of ZIKV for the
central nervous system and other organs (i.e., female and male
genital tract) may provide ZIKV with the ability to escape the
immune system, becoming a silent virus for the host response.
And ﬁnally, ZIKVmay be able to avoid triggering a strong innate
immune response, similar to what has been shown in some cases
of pediatric HIV,[10] because the active viral replication may have
ceased during intrauterine life or soon afterwards. However, we5do not know whether the same IgG dynamic is present in case of
post-natal infection or reinfections, which could be very common
in ZIKV endemic countries.
This case underscores the importance of the clinical and
radiological characteristics in the diagnosis of CZS, given the
challenges in laboratory ascertainment of ZIKV infection in the
perinatal period. Therefore, an approach from the host
perspective using genomic and transcriptomic approaches and
new biomarkers for understanding pathogenesis and improving
diagnosis may ﬁnally give us the tools to solve these difﬁculties in
the future.[3]4. Conclusion
We presume that as a consequence of prenatal ZIKV infection,
the fetal brain and other organs are damaged before birth
through direct injury. Following this, active infection ends during
intrauterine life, and as a consequence the immune system of the
infant is unable to build up a consistent immune response
thereafter. Further understanding of the mechanisms taking part
in the pathogenesis of ZIKV congenital infection is needed.Author contributions
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